KRCA-0713
KRCA-0713 is an ALK inhibitor with anti-ALK activity. KRCA-0713 showed promising anti-ALK activity in enzyme and cell-based experiments. KRCA-0713 was shown to effectively inhibit ALK-driven tumor growth in H3122 xenograft model studies, similar to the effect of ceritinib[1].
Product Specifications
CAS Number
1884321-89-4
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK)
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/krca-0713.html
Smiles
O=S(C1=C(NC2=NC(NC3=C(OC)C=C(C(C)(C(CC4)N)C)C4=C3)=NC=C2Cl)C=CC=C1)(C(C)C)=O
Molecular Formula
C26H32ClN5O3S
Molecular Weight
530.08
References & Citations
[1]Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ATG4B Recombinant Antbody Kit (KD-Validated)
Recombinant Mouse ARAP1 Protein, His (Fc)-Avi-tagged
Recombinant Deinococcus radiodurans Undecaprenyl-diphosphatase (uppP), partial